Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  International Journal of Oncology

• Publication date

  2002-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO.21.5.941PMID 12370739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cripto: A tumor growth factor and more

  2002cited by this paper
• Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts

  2000cited by this paper
• Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells.

  2000cited by this paper
• The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer.

  2000cited by this paper
• EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells.

  2000cited by this paper
• Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families.

  1999cited by this paper
• Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells.

  1999cited by this paper
• EGF‐related peptides are involved in the proliferation and survival of MDA‐MB‐468 human breast carcinoma cells

  1999cited by this paper
• Expression of Epidermal Growth Factor‐Related Proteins and Epidermal Growth Factor Receptor in Common Epithelial Ovarian Tumors

  1997cited by this paper
• Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.

  1997cited by this paper
• Anti‐sense oligonucleotides directed against EGF‐related growth factors enhance anti‐proliferative effect of conventional anti‐tumor drugs in human colon‐cancer cells

  1997cited by this paper
• Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.

  1996cited by this paper
• Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas

  1995cited by this paper
• Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines.

  1995cited by this paper
• RET/PTC oncogene activation is an early event in thyroid carcinogenesis.

  1995cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells.

  1995cited by this paper
• Enhancement of drug sensitivity of human malignancies by epidermal growth factor.

  1995cited by this paper
• Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis.

  1994cited by this paper
• Expression of amphiregulin, cripto-1, and heregulin-alpha in human breast-cancer cells.

  1993cited by this paper
• Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor‐alpha, myc, jun, and metallothionein in human ovarian carcinomas classification of malignant phenotypes

  1993cited by this paper
• Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines.

  1992cited by this paper
• Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors.

  1992cited by this paper
• Significance of epidermal growth factor receptor in advanced ovarian cancer.

  1992cited by this paper
• Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines.

  1992cited by this paper
• Importance of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo.

  1991cited by this paper
• Response to and expression of amphiregulin by ovarian carcinoma and normal ovarian surface epithelial cells: nuclear localization of endogenous amphiregulin.

  1991cited by this paper
• Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro.

  1991cited by this paper
• Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

  1990cited by this paper

• Amphiregulin Downregulates E-cadherin Expression by Activating YAP/Egr-1/Slug Signaling in SKOV3 Human Ovarian Cancer Cells

  2024cites this paper
• Glutamine metabolism controls amphiregulin-facilitated chemoresistance to cisplatin in human chondrosarcoma

  2023cites this paper
• Differential Effects of Iron Chelates vs. Iron Salts on Induction of Pro-Oncogenic Amphiregulin and Pro-Inflammatory COX-2 in Human Intestinal Adenocarcinoma Cell Lines

  2023cites this paper
• Oncofetal protein CRIPTO regulates wound healing and fibrogenesis in regenerating liver and is associated with the initial stages of cardiac fibrosis

  2021cites this paper
• Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis

  2021cites this paper
• Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis

  2021cites this paper
• Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling.

  2021cites this paper
• Cripto-1 as a Key Factor in Tumor Progression, Epithelial to Mesenchymal Transition and Cancer Stem Cells

  2021cites this paper
• Complement membrane attack and tumorigenesis : a systems biology approach

  2020cites this paper
• The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion

  2019cites this paper
• Cripto-1: potential target for cancer immunotherapy?!

  2019cites this paper
• Secreted amphiregulin promotes vincristine resistance in oral squamous cell carcinoma.

  2019cites this paper
• Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells

  2019cites this paper
• Targeting Nodal and Cripto-1: perspectives inside dual potential theranostic cancer biomarkers.

  2018cites this paper
• Amphiregulin enhances cell migration and resistance to doxorubicin in chondrosarcoma cells through the MAPK pathway

  2018cites this paper
• CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma

  2018cites this paper
• High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.

  2018cites this paper
• Cell Therapy for Parkinson’s Disease

  2017cites this paper
• A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα-TGFα-EGFR

  2017cites this paper
• Signalisation nucléaire de l'IGF-1R et résistance aux thérapies anti-EGFR dans les cancers du poumon

  2016cites this paper
• Expression of amphiregulin in mucoepidermoid carcinoma of the major salivary glands: a molecular and clinicopathological study.

  2016cites this paper
• Complement Membrane Attack and Tumorigenesis

  2016cites this paper
• Transforming growth factor-α induces human ovarian cancer cell invasion by down-regulating E-cadherin in a Snail-independent manner.

  2015cites this paper
• Activins and activin antagonists in the human ovary and ovarian cancer.

  2015cites this paper
• CRIPTO1: expressão e possíveis ações sobre as células citotrofoblásticas extravilosas humanas.

  2015cites this paper
• Roles of epidermal growth factor receptor and its ligands in ovarian cancer

  2015cites this paper
• Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway

  2015cites this paper
• Cripto‐1 Expression in Glioblastoma Multiforme

  2014cites this paper
• Clinicopathological and biological significance of cripto overexpression in human colon cancer.

  2013cites this paper
• Androgen/androgen receptor pathway regulates expression of the genes for cyclooxygenase-2 and amphiregulin in periovulatory granulosa cells.

  2013cites this paper
• Molecular targeted therapy in epithelial ovarian cancer

  2013cites this paper
• Investigating the tumour promoting roles of complement membrane attack complex using global gene expression analysis.

  2013cites this paper
• Normal range of serum Amphiregulin in healthy adult human females.

  2012cites this paper
• Serum Levels of Epidermal Growth Factor, Transforming Growth Factor, and c-erbB2 in Ovarian Cancer

  2012cites this paper
• Transforming Growth Factor Alpha (TGFα) Regulates Granulosa Cell Tumor (GCT) Cell Proliferation and Migration through Activation of Multiple Pathways

  2012cites this paper
• 5.34 – Cell Therapy for Parkinson’s Disease

  2011cites this paper
• The multiple roles of amphiregulin in human cancer.

  2011cites this paper
• Epiregulin as a marker for the initial steps of ovarian cancer development.

  2011cites this paper
• Amphiregulin (AREG) and epidermal growth factor (EGF): Disparate in EGFR signaling and trafficking

  2011cites this paper
• Knock‐down of amphiregulin inhibits cellular invasion in inflammatory breast cancer

  2011cites this paper
• An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.

  2011cites this paper
• The Human Adenocarcinoma-associated Gene, AGR2, Induces Expression of Amphiregulin through Hippo Pathway Co-activator YAP1 Activation*

  2011cites this paper
• AREG (amphiregulin (schwannoma -derived growth factor))

  2011cites this paper
• Expression and functional role of CRIPTO-1 in cutaneous melanoma

  2011cites this paper
• ErbB/EGF Signaling and EMT in Mammary Development and Breast Cancer

  2010cites this paper
• The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.

  2010cites this paper
• BRCA1 represses amphiregulin gene expression.

  2010cites this paper
• TDGF1 is a novel predictive marker for metachronous metastasis of colorectal cancer.

  2010cites this paper
• Cripto-1: an embryonic gene that promotes tumorigenesis.

  2010cites this paper
• Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties.

  2009cites this paper
• Rôle de l'amphiréguline dans la résistance du cancer du poumon non-à petites cellules au gefitinib

  2008cites this paper
• Immunotherapy for head and neck cancer.

  2008cites this paper
• Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

  2008cites this paper
• Expression and prognostic significance of the EGFR in solid tumors

  2008cites this paper
• Positive association of up‐regulated Cripto‐1 and down‐regulated E‐cadherin with tumour progression and poor prognosis in gastric cancer

  2008cites this paper
• Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor

  2008cites this paper
• Cripto-1 expression in uveal melanoma: an immunohistochemical study.

  2007cites this paper
• Amphiregulin: a new growth factor in hepatocarcinogenesis.

  2007cites this paper
• Stem Cell Transplantation: A Promising Therapy for Parkinson’s Disease

  2007cites this paper
• Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.

  2007cites this paper
• Hypoxia induces epithelial amphiregulin gene expression in a CREB-dependent manner.

  2006cites this paper
• Novel function of ovarian growth factors: combined studies by DNA microarray, biochemical and physiological approaches.

  2006cites this paper
• MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma

  2006cites this paper
• Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma.

  2006cites this paper
• Relevant molecular markers and targets.

  2006cites this paper
• The ErbB receptors and their ligands in cancer: an overview.

  2005cites this paper
• Clinical Significance of Heparin-Binding Epidermal Growth Factor–Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer

  2005cites this paper
• Selection de patients pour une therapie avec un inhibiteur de her

  2005cites this paper
• Increase inAmphiregulin and Epiregulin in Prostate CancerXenograftAfterAndrogenDeprivation

  2005cites this paper
• Cripto as a target for cancer immunotherapy

  2005cites this paper
• Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation—impact of specific HER1 inhibition

  2005cites this paper
• Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer

  2005cites this paper
• Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis.

  2005cites this paper
• Cripto-1: an oncofetal gene with many faces.

  2005cites this paper
• Drug development for ovarian hyper-stimulation and anti-cancer treatment: blocking of gonadotropin signaling for epiregulin and amphiregulin biosynthesis.

  2004cites this paper
• Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy

  2004cites this paper
• CRIPTO-1: a novel target for therapeutic intervention in human carcinoma.

  2004cites this paper
• Inhibin/activin and ovarian cancer.

  2004cites this paper
• Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases.

  2004cites this paper
• Cripto: a novel target for antibody-based cancer immunotherapy.

  2004cites this paper
• [HER-ErbB family of receptors and their ligands: mechanisms of activation, signals and deregulation in cancer].

  2003cites this paper
• Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.

  2003cites this paper
• TDGF 1 is a novel predictive marker for metachronous metastasis of colorectal cancer

  year unknowncites this paper